Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07179601 · ClinicalTrials.gov registry record · NA
Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS)
A NA study of HAE and Internal Hemorrhoids, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT07179601: Recruiting NA study of HAE and Internal Hemorrhoids, sponsored by University of California, Los Angeles.
NCT07179601 is a NA study of HAE and Internal Hemorrhoids that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07179601, a NA study of HAE and Internal Hemorrhoids, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
Hemorrhoidal artery embolization (HAE) is a novel treatment for symptomatic internal hemorrhoids. HAE involves the deliberate blockage (embolization) of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve hemorrhoid related symptoms, especially bleeding. Initial reports of HAE have demonstrated that it both safe and effective. Following an initial clinic visit to determine trial candidacy, enrolled patients will be subsequently treated with HAE. Patients will be followed for a year with clinic follow-up visits at 1, 3, 6 and 12 months.
Conditions Studied
Interventions
- PROCEDURE Hemorrhoidal artery embolization
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2025-08-05 |
| Est. Completion | 2029-09-30 |
| Phase | NA |
What NCT07179601 shows while recruiting
NCT07179601 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with HAE appearing as the primary indexed condition, and to 1 intervention - of which Hemorrhoidal artery embolization is the first listed.
NCT07179601 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07179601 about?
NCT07179601 is a clinical study titled "Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS)". Hemorrhoidal artery embolization (HAE) is a novel treatment for symptomatic internal hemorrhoids. HAE involves the deliberate blockage (embolization) of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve h...
What is the current status of trial NCT07179601?
This trial is currently recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2025-08-05. Estimated completion is 2029-09-30.
What conditions does trial NCT07179601 study?
This clinical trial studies the following conditions: HAE, Internal Hemorrhoids.
What interventions are being tested in trial NCT07179601?
The interventions under investigation include: Hemorrhoidal artery embolization (PROCEDURE).
Who is sponsoring clinical trial NCT07179601?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07179601 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HAE
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07179601's enrollment target sits among peer trials
22 1757th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI